• Cubist Pharmaceuticals Inc., of Lexington, Mass., completed its acquisition of Adolor Corp. for approximately $221 million. All outstanding shares of Adolor were acquired for $4.25 per share in up-front cash plus one contingent payment right per share, entitling the holder to receive additional cash payments of up to $4.50 for each share owned if certain regulatory approvals and/or commercialization milestones for ADL5945 are achieved.